Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-II TRIALS OF 5-FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC GASTRIC OR PANCREATIC-CARCINOMA
Autore:
RUBIN J; GALLAGHER JG; SCHROEDER G; SCHUTT AJ; DALTON RJ; KUGLER JW; MORTON RF; MAILLIARD JA; BURCH PA;
Indirizzi:
MAYO CLIN & MAYO FDN,DEPT ONCOL,200 1ST ST SW ROCHESTER MN 55905 WEIS CTR RES,GEISINGER CLIN,ONCOL PROGRAM DANVILLE PA 17822 DULUTH COMMUN CLIN ONCOL PROGRAM DULUTH MN 00000 ILLINOIS ONCOL RES ASSOC CCOP PEORIA IL 00000 IOWA ONCOL RES ASSOC CCOP DES MOINES IA 00000 CREIGHTON UNIV UNIV NEBRASKA MED CTR & ASSOCIATES,NEBRASKA ONCOL GRP OMAHA NE 00000
Titolo Testata:
Cancer
fascicolo: 9, volume: 78, anno: 1996,
pagine: 1888 - 1891
SICI:
0008-543X(1996)78:9<1888:PTO5AL>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE LEUCOVORIN; ADVANCED COLORECTAL-CARCINOMA; PREVIOUSLY UNTREATED PATIENTS; COMBINATION CHEMOTHERAPY; ADVANCED ADENOCARCINOMA; RANDOMIZED TRIAL; CANCER; FLUOROURACIL; ADRIAMYCIN; MITOMYCIN;
Keywords:
5-FLUOROURACIL; LEUCOVORIN; GASTRIC CARCINOMA; PANCREATIC CARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
J. Rubin et al., "PHASE-II TRIALS OF 5-FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC GASTRIC OR PANCREATIC-CARCINOMA", Cancer, 78(9), 1996, pp. 1888-1891

Abstract

BACKGROUND. Previous trials in patients with colorectal carcinoma have indicated that enhancement of 5-fluorouracil (5-FU) by leucovorin (LV) can result in an improved response rate and increased survival. METHODS. Phase II trials were performed with patients who had either gastric or pancreatic adenocarcinoma with metastases. Forty-one gastric carcinoma patients and 31 pancreatic carcinoma patients with measurable disease were treated with 5-FU, 425 mg/m(2) intravenously (i.v.), on Days 1-5 plus LV, 20 mg/m(2) i.v., on Days 1-5, repeated at 4 and 8 weeks, and then every 5 weeks thereafter. RESULTS. The patients with metastatic gastric carcinoma had a median survival of 4.8 months. There was a 22% objective response rate, including a 4.9% complete response rate and a 17.1% partial response rate. Among the 31 patients with pancreatic carcinoma, there was a median survival of 5.7 months. No patients in this group showed a response. CONCLUSIONS. The response rate for patients with metastatic gastric adenocarcinoma was modest and this regimen may provide temporary palliation for some patients. However, 5-FU and LV treatment is ineffective against metastatic pancreatic carcinoma. (C) 1996 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 05:37:09